๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Compound trial record
Trackers Drugs Trial finder
Compound · clinical trials

Binimetinib

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 5 trials in our USA, UK and China registers that name Binimetinib as an intervention. Synced 24 Sep 2026
5Trials tracked
1Recruiting now
4Lead sponsors
3Country registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 โ€” Top 14 finalist
Compiled from ClinicalTrials.gov registry records ยท Last verified ยท Editorial standards

Binimetinib is named as a drug or biological intervention in 5 clinical trials in our USA, UK and China trial registers, 1 of which is recruiting. Lead sponsors include Pfizer (2), Pierre Fabre Ltd (1) and IDEAYA Biosciences (1). Registered phases: Phase 3, Observational, Phase 1/2, Phase 1 and Phase 2. Conditions studied include Melanoma; Metastatic Melanoma, BRAF V600 Mutation Positive; Metastatic Uveal Melanoma.

01

Clinical trials of Binimetinib

5 trials
NCT IDStudyPhaseStatusLead sponsorRegister
NCT03947385 Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions (ClinicalTrials.gov ↗)
Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer
Phase 1/2 Recruiting IDEAYA Biosciences USA
NCT04657991 A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma (ClinicalTrials.gov ↗)
Melanoma
Phase 3 Active, closed Pfizer UK, USA
NCT05195632 Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer (ClinicalTrials.gov ↗)
Non-Small Cell Lung Cancer
Phase 2 Active, closed Pierre Fabre Medicament China
NCT05355701 A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. (ClinicalTrials.gov ↗)
Melanoma, Non-Small-Cell Lung Cancer, Thyroid Cancer
Phase 1 Active, closed Pfizer USA
NCT07022457 UK ENcorafenib and BInimetinib Real-world Study in Melanoma (ClinicalTrials.gov ↗)
Metastatic Melanoma, BRAF V600 Mutation Positive
Observational Active, closed Pierre Fabre Ltd UK

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied

10 conditions
Condition (as registered)Trials
Melanoma2
Metastatic Melanoma, BRAF V600 Mutation Positive1
Metastatic Uveal Melanoma1
Cutaneous Melanoma1
Colorectal Cancer1
Other Solid Tumors1
Non-Small-Cell Lung Cancer1
Thyroid Cancer1
Glioma1
Non-Small Cell Lung Cancer1
03

Sponsors

lead sponsor per trial
Lead sponsorTrials
Pfizer2
Pierre Fabre Ltd1
IDEAYA Biosciences1
Pierre Fabre Medicament1
04

Trials by country register

A trial with sites in more than one country appears in each of those registers.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records โ€” it is not written from memory, and nothing here describes how Binimetinib works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Binimetinib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician โ€” our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us โ€” we correct promptly and log it.